Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Last trade$2.59
Day change-$0.015 (-0.58%)
Day range$2.49 – $2.77
Volume987,249
Market cap$160M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$160.27M
Price / earnings
—
Price / book
1.27×
Price / sales
4.11×
EV / sales
2.71×
EV / EBITDA
-1.52×
Profitability
Earnings per share
-$1.01
Return on assets
-36.37%
Return on equity
-49.68%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.09×
Current ratio
5.69×
Quick ratio
5.52×
Cash ratio
2.39×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$66.35M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ABEO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$13.49M
$11.38M
$8.72M
$5.42M
$0
$400K
$0
$0
Cost of revenue
$5.71M
$4.18M
$2.7M
$1.04M
$488K
$0
$0
$0
Gross profit
$7.78M
$7.2M
$6.02M
$4.38M
-$488K
$400K
$0
$0
Selling, general and administrative
$17.11M
$15.84M
$19.5M
$18.78M
$19.31M
$17.15M
$9.79M
$7.68M
Research and development
$3.67M
$5.02M
$9.56M
$6.71M
$4.22M
$5.94M
$9.94M
$8.99M
Total operating expenses
$20.78M
$20.86M
$29.06M
$27.29M
$23.53M
$23.19M
$19.73M
$16.67M
Operating income
-$13M
-$13.65M
-$23.03M
-$22.91M
-$24.02M
-$22.79M
-$19.73M
-$16.67M
Interest expense
-$557K
-$696K
-$830K
-$884K
-$901K
-$957K
-$998K
-$1.08M
Income before taxes
-$4.79M
-$20.19M
-$17.07M
-$20.68M
-$20.36M
$124.35M
-$12.03M
-$9.29M
Income taxes
$18K
$0
$2K
-$215K
-$15.2M
$15.51M
$0
$0
Net income
-$4.81M
-$20.19M
-$17.08M
-$20.46M
-$5.16M
$108.83M
-$12.03M
-$9.29M
Net income attributable to common shareholders
-$4.81M
-$20.19M
-$17.08M
-$20.46M
-$5.16M
$108.83M
-$12.03M
-$9.29M
EBITDA
-$12.3M
-$12.99M
-$22.34M
-$22.05M
-$23.41M
-$22.25M
-$19.19M
-$16.13M
Basic earnings per share
-$0.08
-$0.35
-$0.30
-$0.37
-$0.10
$2.07
-$0.24
-$0.19
Diluted earnings per share
-$0.08
-$0.35
-$0.30
-$0.22
-$0.10
$1.71
-$0.24
-$0.25
Recent news
Company coverage with links to the original publishers.
Pomerantz LLP is investigating potential securities fraud claims against Abeona Therapeutics following the company's August 13, 2026 disclosure that only four of five patient treatments with ZEVASKYN were recognized for revenue due to one batch lacking minimum sheet requirements. The announcement triggered a 14.95% stock price decline.
Pomerantz LLP announced investigations into potential securities fraud at Abeona Therapeutics following disclosure that only 4 of 5 ZEVASKYN treatments were recognized for revenue due to one batch lacking minimum sheet requirements. The stock fell 14.95% to $6.35 on August 13, 2026. Similar investigations were initiated for JinkoSolar and Stitch Fix.
Pomerantz Law Firm has filed class action lawsuits against Babcock & Wilcox Enterprises, Inc. (BW) on behalf of investors who acquired securities between November 5, 2025, and March 11, 2026. The firm is also investigating claims on behalf of investors in Abeona Therapeutics Inc. (ABEO) and has announced a class action lawsuit against AST SpaceMobile, Inc. (ASTS) and certain officers.
Abeona Therapeutics Inc. (Nasdaq: ABEO) granted restricted stock equity awards to five new non-executive employees on June 30, 2026, totaling up to 9,000 restricted shares as a material inducement to employment. The shares will vest over three years with one-third vesting annually, subject to continued employment.
Abeona Therapeutics Inc. announced the grant of restricted stock equity awards to seven new employees on December 30, 2025, totaling up to 79,584 restricted shares. The awards vest over three years subject to continued employment. The grants were approved under Nasdaq Listing Rule 5635(c)(4) as material inducement to employment.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.